AUTHOR=Du Na , Yang Jingyi , Zhang Yiwen , Lv Xinyan , Cao Lei , Min Wei 

TITLE=Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients

JOURNAL=Frontiers in Medicine

VOLUME=Volume 11 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1476793

DOI=10.3389/fmed.2024.1476793

ISSN=2296-858X

ABSTRACT=Background: Upadacitinib, a specific JAK1 inhibitor, has minimal effect on other JAK subtypes. It influences the inflammatory process in various ways. Upadacitinib has been approved for conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ulcerative colitis in various countries. The purpose of this study is to assess the clinical efficacy and safety of upadacitinib in patients with refractory palmoplantar pustulosis who have not responded to conventional treatments(e.g.Acitretin, Tripterygium wilfordii Hook F, cyclosporine, methotrexate).We conducted a retrospective collection of clinical data from 28 patients who received upadacitinib treatment at the